The Swiss dental startup Odne has raised USD 5.5m to fund the upcoming US market launch for their minimal invasive Root Preservation Technology (RPT). The Series A1 round for Odne, was led by Revere Partners (
Tags :Matthias Staehelin
GlycoEra AG in Wädenswil, has increased its Series A Financing Round with a substantial additional investment by Bristol Meyer Squibb (BMS) to further support the development of its innovative platform to enable high-throughput design
Proteomedix, a Swiss private, commercial-stage diagnostics oncology company and Water Biotech are forming together a company called Onconetix. The transaction is implemented by the acquisition of Proteomedix for an all stock consideration. Onconetix’s commercial
Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, has announced the completion of its oversubscribed Series C equity financing raising EUR 67.5m (USD 72m) from a syndicate
Memo Therapeutics, a late-stage biotech company developing best-in-class therapeutic antibodies closed a CHF 25 million series C financing round led by Pureos Bioventures. Existing investors Swisscanto, Vesalius Biocapital, Adjuvant Capital, Verve Ventures, Schroders Capital, GF Group,
Vischer acted as legal advisor to LimmaTech Biologics as it successfully concluded a USD 37 million (CHF 33 million) Series A financing round, co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund.
Luciole Medical, a Swiss medical technology company specialized in brain monitoring, acquires Spiegelberg & Co., an established medical device company and provider of highly specialized devices and consumables for neurosurgery, from SHS Capital. Spiegelberg has
Oculis Holding, a global biopharmaceutical company purposefully driven to save sight and improve eye care, has placed a follow-on public offering of 3.5m ordinary shares at a public offering price of USD 11.50 per ordinary share,
Mosanna Therapeutics, a Basel-based biotechnology company developing the highly differentiated small molecule MOS118 for the treatment of metabolic obstructive sleep apnea, has closed an extension of the Seed Financing Round with the investors Supermoon Capital,
Intel Capital, an investor in the future of compute, has invested in Unisers, a Swiss semiconductor metrology company that identifies invisible contamination-caused defects in semiconductor materials. The USD14 million seed financing round was led